0001127602-21-000541.txt : 20210105
0001127602-21-000541.hdr.sgml : 20210105
20210105162420
ACCESSION NUMBER: 0001127602-21-000541
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210104
FILED AS OF DATE: 20210105
DATE AS OF CHANGE: 20210105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zaks Tal Zvi
CENTRAL INDEX KEY: 0001690927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 21505915
MAIL ADDRESS:
STREET 1: 122 BELLEVUE STREET
CITY: NEWTON
STATE: MA
ZIP: 02458
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2021-01-04
0001682852
Moderna, Inc.
MRNA
0001690927
Zaks Tal Zvi
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
Chief Medical Officer
Common Stock
2021-01-04
4
M
0
5000
12.21
A
5000
D
Common Stock
2021-01-04
4
S
0
100
103.51
D
4900
D
Common Stock
2021-01-04
4
S
0
600
105.07
D
4300
D
Common Stock
2021-01-04
4
S
0
445
106.52
D
3855
D
Common Stock
2021-01-04
4
S
0
400
108.02
D
3455
D
Common Stock
2021-01-04
4
S
0
1802
110.09
D
1653
D
Common Stock
2021-01-04
4
S
0
1253
111.14
D
400
D
Common Stock
2021-01-04
4
S
0
300
112.29
D
100
D
Common Stock
2021-01-04
4
S
0
100
112.96
D
0
D
Stock Option (Right to Buy)
12.21
2021-01-04
4
M
0
5000
0
D
2027-10-03
Common Stock
5000
189952
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.78 to $105.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.90 to $106.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.74 to $108.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.69 to $110.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.73 to $111.60 Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.74 to $112.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
/s/ Lori Henderson, as Attorney-in-Fact
2021-01-05